Faron Pharmaceuticals released FY19 results

  • During the year 2019, the company generated “Zero” revenue as compared to the previous year
  • Research and development expenses decreased to €10.2 million versus €16.5 million during the year 2018
  • Operating loss decreased to €13.1 million as compared to €19.9 million during the year 2018.
  • The company did not recommend any dividend during the period.

Comment


Disclaimer